Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists

Alison M. Badger, Jean Young, George Poste

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effect of a series of structurally-diverse histamine type II (H2)-receptor antagonists on histamine-mediated immunosuppression of human peripheral blood lymphocytes (HPBL) has been examined. This analysis of structure-activity relationships was undertaken to examine the validity of the recent proposal arising from clinical studies that H2-receptor antagonists containing a furan ring were devoid of the effects on lymphocyte function reported previously in studies using cimetidine and other H2-receptor antagonists containing an imidazole nucleus. Cimetidine and two furan-containing antagonists, ranitidine and SKF 93479, were found to be devoid of any effect of PHA-induced proliferation of human peripheral blood lymphocytes over a wide concentration range (10-4 to 10-10M). At high drug concentrations (10-3M) significant suppression of mitogen stimulation was observed but this was accompanied by significant cytotoxicity. All three antagonists were effective in reversing the suppression of PHA-stimulation of HPBL induced by exogenous histamine. Reversal of histamine-induced immunosuppression was obtained at drug concentrations (2.0 × 10-4 to 1.0 × 10-6M) which were non-toxic and did not affect PHA-induced proliferation in the absence of histamine. Ranitidine was the most potent antagonist in reversing histamine-mediated immunosuppression. The ability of structurally-diverse H2-receptor antagonists to modify the action of histamine on lymphocyte function lends support to the view that histamine exerts its effects via classical H2-receptors. The ability of ranitidine to alter lymphocyte responsiveness in analogous fashion to cimetidine indicates that the possibility of alterations in immune function should be considered in clinical studies using ranitidine and other furan-containing H2-receptor antagonists.

Original languageEnglish (US)
Pages (from-to)467-473
Number of pages7
JournalInternational Journal of Immunopharmacology
Volume6
Issue number5
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Histamine H2 Antagonists
Immunosuppression
Histamine
Histamine H2 Receptors
Ranitidine
Lymphocytes
Cimetidine
Structure-Activity Relationship
Mitogens
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists. / Badger, Alison M.; Young, Jean; Poste, George.

In: International Journal of Immunopharmacology, Vol. 6, No. 5, 1984, p. 467-473.

Research output: Contribution to journalArticle

@article{92b4b2e4edbb47af96bdea7ff884376b,
title = "Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists",
abstract = "The effect of a series of structurally-diverse histamine type II (H2)-receptor antagonists on histamine-mediated immunosuppression of human peripheral blood lymphocytes (HPBL) has been examined. This analysis of structure-activity relationships was undertaken to examine the validity of the recent proposal arising from clinical studies that H2-receptor antagonists containing a furan ring were devoid of the effects on lymphocyte function reported previously in studies using cimetidine and other H2-receptor antagonists containing an imidazole nucleus. Cimetidine and two furan-containing antagonists, ranitidine and SKF 93479, were found to be devoid of any effect of PHA-induced proliferation of human peripheral blood lymphocytes over a wide concentration range (10-4 to 10-10M). At high drug concentrations (10-3M) significant suppression of mitogen stimulation was observed but this was accompanied by significant cytotoxicity. All three antagonists were effective in reversing the suppression of PHA-stimulation of HPBL induced by exogenous histamine. Reversal of histamine-induced immunosuppression was obtained at drug concentrations (2.0 × 10-4 to 1.0 × 10-6M) which were non-toxic and did not affect PHA-induced proliferation in the absence of histamine. Ranitidine was the most potent antagonist in reversing histamine-mediated immunosuppression. The ability of structurally-diverse H2-receptor antagonists to modify the action of histamine on lymphocyte function lends support to the view that histamine exerts its effects via classical H2-receptors. The ability of ranitidine to alter lymphocyte responsiveness in analogous fashion to cimetidine indicates that the possibility of alterations in immune function should be considered in clinical studies using ranitidine and other furan-containing H2-receptor antagonists.",
author = "Badger, {Alison M.} and Jean Young and George Poste",
year = "1984",
doi = "10.1016/0192-0561(84)90085-7",
language = "English (US)",
volume = "6",
pages = "467--473",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Reversal of histamine-mediated immunosuppression by structurally diverse histamine type II (H2) receptor antagonists

AU - Badger, Alison M.

AU - Young, Jean

AU - Poste, George

PY - 1984

Y1 - 1984

N2 - The effect of a series of structurally-diverse histamine type II (H2)-receptor antagonists on histamine-mediated immunosuppression of human peripheral blood lymphocytes (HPBL) has been examined. This analysis of structure-activity relationships was undertaken to examine the validity of the recent proposal arising from clinical studies that H2-receptor antagonists containing a furan ring were devoid of the effects on lymphocyte function reported previously in studies using cimetidine and other H2-receptor antagonists containing an imidazole nucleus. Cimetidine and two furan-containing antagonists, ranitidine and SKF 93479, were found to be devoid of any effect of PHA-induced proliferation of human peripheral blood lymphocytes over a wide concentration range (10-4 to 10-10M). At high drug concentrations (10-3M) significant suppression of mitogen stimulation was observed but this was accompanied by significant cytotoxicity. All three antagonists were effective in reversing the suppression of PHA-stimulation of HPBL induced by exogenous histamine. Reversal of histamine-induced immunosuppression was obtained at drug concentrations (2.0 × 10-4 to 1.0 × 10-6M) which were non-toxic and did not affect PHA-induced proliferation in the absence of histamine. Ranitidine was the most potent antagonist in reversing histamine-mediated immunosuppression. The ability of structurally-diverse H2-receptor antagonists to modify the action of histamine on lymphocyte function lends support to the view that histamine exerts its effects via classical H2-receptors. The ability of ranitidine to alter lymphocyte responsiveness in analogous fashion to cimetidine indicates that the possibility of alterations in immune function should be considered in clinical studies using ranitidine and other furan-containing H2-receptor antagonists.

AB - The effect of a series of structurally-diverse histamine type II (H2)-receptor antagonists on histamine-mediated immunosuppression of human peripheral blood lymphocytes (HPBL) has been examined. This analysis of structure-activity relationships was undertaken to examine the validity of the recent proposal arising from clinical studies that H2-receptor antagonists containing a furan ring were devoid of the effects on lymphocyte function reported previously in studies using cimetidine and other H2-receptor antagonists containing an imidazole nucleus. Cimetidine and two furan-containing antagonists, ranitidine and SKF 93479, were found to be devoid of any effect of PHA-induced proliferation of human peripheral blood lymphocytes over a wide concentration range (10-4 to 10-10M). At high drug concentrations (10-3M) significant suppression of mitogen stimulation was observed but this was accompanied by significant cytotoxicity. All three antagonists were effective in reversing the suppression of PHA-stimulation of HPBL induced by exogenous histamine. Reversal of histamine-induced immunosuppression was obtained at drug concentrations (2.0 × 10-4 to 1.0 × 10-6M) which were non-toxic and did not affect PHA-induced proliferation in the absence of histamine. Ranitidine was the most potent antagonist in reversing histamine-mediated immunosuppression. The ability of structurally-diverse H2-receptor antagonists to modify the action of histamine on lymphocyte function lends support to the view that histamine exerts its effects via classical H2-receptors. The ability of ranitidine to alter lymphocyte responsiveness in analogous fashion to cimetidine indicates that the possibility of alterations in immune function should be considered in clinical studies using ranitidine and other furan-containing H2-receptor antagonists.

UR - http://www.scopus.com/inward/record.url?scp=0021199204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021199204&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(84)90085-7

DO - 10.1016/0192-0561(84)90085-7

M3 - Article

C2 - 6150013

AN - SCOPUS:0021199204

VL - 6

SP - 467

EP - 473

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 5

ER -